Efficacy and safety of statins in ethnic differences: a lesson for application in Indigenous Australian patient care

References

• 1. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112(1), 71–105 (2006).
  Medline CASGoogle Scholar
• 2. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J. Am. Coll. Cardiol. 61(25), 2495–2502 (2013).
  Medline CASGoogle Scholar
• 3. Ieiri S, Higuchi I, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol. 5(7), 703–729 (2009).
  Medline CASGoogle Scholar
• 4. Wang EJ, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res. 18(6), 800–806 (2001).
  Medline CASGoogle Scholar
• 5. Ho RH, Tirona RG, Leake BF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130(6), 1793–1806 (2006).
  Medline CASGoogle Scholar
• 6. Schachter Michael. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19(1), 117–125 (2005).
  Medline CASGoogle Scholar
• 7. Ballantyne CM. Section III therapy. Clinical lipidology: a companion to Braunwald’s heart disease. Elsevier 254 (2014).
  Google Scholar
• 8. World Health Organization (WHO). Cardiovascular diseases (CVDs) 2017. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  Google Scholar
• 9. Australian Government Department of Health. Cardiovascular disease 2016. http://www.health.gov.au/
  Google Scholar
• 10. Australian Health Minister’s Advisory Council.Aboriginal and Torres Strait Islander Health Performance Framework 2012 Report (2012). https://www1.health.gov.au/internet/main/Publishing.nsf/Content/F766FC3D8A697685CA257BF0001C96E8/$File/hpf-2012.pdf
  Google Scholar
• 11. Australian Bureau of Statistics (ABS). Australia's leading causes of death, 2018 (2019). https://www.abs.gov.au/statistics/health/causes-death/causes-death-australia/2018
  Google Scholar
• 12. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 28(19), 2375–2414 (2007).
  MedlineGoogle Scholar
• 13. Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst.Rev. 31(1), CD004816 (2013).
  Google Scholar
• 14. Stancu C, Sima A. Statins: mechanism of action and effects. J. Cell. Mol. Med. 5(4), 378–387 (2001).
  Medline CASGoogle Scholar
• 15. Ofori-Asenso R, Ilomaki J, Zomer E, Curtis AJ, Zoungas S, Liew D. A 10-year trend in statin use among older adults in Australia: an analysis using National Pharmacy Claims Data. Cardiovasc. Drugs Ther. 32(3), 265–272 (2018).
  MedlineGoogle Scholar
• 16. Gupta M, Braga MFB, Teoh H, Tsigoulis M, Verma S. Statin effects on LDL and HDL cholesterol in South Asian and white populations. J. Clin. Pharmacol. 49(7), 831–837 (2009).
  Medline CASGoogle Scholar
• 17. Hippisley-Cox Julia, Coupland Carol. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 340, c2197 (2010).
  MedlineGoogle Scholar
• 18. Gu Q, Paulose-Ram R, Burt VL, BK K. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. In: NCHS Data Brief. No. 177. National Center for Health Statistics, MD, USA (2014).
  Google Scholar
• 19. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. 40(4), 263–281 (2001).
  Medline CASGoogle Scholar
• 20. Gazzerro P, Proto MC, Gangemi G et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64(1), 102 (2012).
  Medline CASGoogle Scholar
• 21. Fischer V, Johanson L, Heitz F et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27(3), 410–416 (1999).
  Medline CASGoogle Scholar
• 22. Yang D-J, Hwang LS. Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea. J. Chromatogr. A 1119(1), 277–284 (2006).
  Medline CASGoogle Scholar
• 23. Kellick KA, Bottorff M, Toth PP. A clinician’s guide to statin drug–drug interactions. J. Clin. Lipidol. 8(3), S30–S46 (2014).
  MedlineGoogle Scholar
• 24. Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274(52), 37161–37168 (1999).
  Medline CASGoogle Scholar
• 25. Haffner SM, D'Agostino Jr R, Goff D et al. LDL size in African–Americans, Hispanics, and Non-Hispanic whites. Arterioscler. Thromb. Vasc. Biol. 19(9), 2234–2240 (1999).
  Medline CASGoogle Scholar
• 26. Haffner SM, Mykkänen L, Valdez RA, Paidi M, Stern MP, Howard BV. LDL size and subclass pattern in a biethnic population. Arteriosclerosis and thrombosis. J. Vasc. Biol. 13(11), 1623–1630 (1993).
  CASGoogle Scholar
• 27. Kulkarni KR, Markovitz JH, Nanda NC, Segrest JP. Increased prevalence of smaller and denser LDL particles in Asian Indians. Arterioscler. Thromb. Vasc. Biol. 19, 2749–2755 (1999).
  Medline CASGoogle Scholar
• 28. Cho HK, Shin G, Ryu SK, Jang Y, Day SP, Stewart G et al. Regulation of small dense LDL concentration in Korean and Scottish men and women. Atherosclerosis 164(1), 187–193 (2002).
  MedlineGoogle Scholar
• 29. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260(13), 1917–1921 (1988).
  Medline CASGoogle Scholar
• 30. Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid. Med. Cell. Longevity. 2017, 10 (2017).
  Google Scholar
• 31. Orekhov AN, Tertov VV, Mukhin DN. Desialylated low density lipoprotein--naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis 86(2–3), 153–161 (1991).
  Medline CASGoogle Scholar
• 32. Thongtang N, Diffenderfer MR, Ooi EMM et al. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. J. Lipid Res. 58(7), 1315–1324 (2017).
  Medline CASGoogle Scholar
• 33. Hua J, Malinski T. Variable effects of LDL subclasses of cholesterol on endothelial nitric oxide/peroxynitrite balance: the risks and clinical implications for cardiovascular disease. Int. J. Nanomedicine 14, 8973–8987 (2019).
  Medline CASGoogle Scholar
• 34. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106(15), 1930–1937 (2002).
  Medline CASGoogle Scholar
• 35. Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in Type 2 diabetes. Metabolism 54(2), 227–234 (2005).
  Medline CASGoogle Scholar
• 36. Fan J, Liu Y, Yin S et al. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation. Nutr. Metab. (Lond.) 16, 7 (2019).
  Google Scholar
• 37. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83(1), 59–67 (1990).
  Medline CASGoogle Scholar
• 38. Packard CJ. Evolution of the HMG CoA reductase inhibitors (statins) in cardiovascular medicine. Br. J. Cardiol. 11(2), 129–136 (2004).
  Google Scholar
• 39. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol. 105(1), 69–76 (2010).
  Medline CASGoogle Scholar
• 40. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am. J. Cardiol. 92(2), 152–160 (2003).
  Medline CASGoogle Scholar
• 41. Shuhaili MFRMA, Samsudin IN, Stanslas J, Hasan S, Thambiah SC. Effects of different types of statins on lipid profile: a perspective on Asians. Int. J. Endocrinol. Metab. 15(2), e43319 (2017).
  MedlineGoogle Scholar
• 42. Oni-Orisan A, Hoffmann TJ, Ranatunga D et al. Characterization of statin low-density lipoprotein cholesterol dose-response using electronic health records in a large population-based cohort. Circ. Genomic Precis. Med. 11(9), e002043 (2018).
  CASGoogle Scholar
• 43. Yood MU, McCarthy BD, Kempf J et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am. Heart J. 152(4), 777–784 (2006).
  Medline CASGoogle Scholar
• 44. Clark LT, Maki KC, Galant R, Maron DJ, Pearson TA, Davidson MH. Ethnic differences in achievement of cholesterol treatment goals: results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J. Gen. Intern. Med. 21(4), 320–326 (2006).
  MedlineGoogle Scholar
• 45. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton Jr VP, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821–2827 (2004).
  Medline CASGoogle Scholar
• 46. Kouji K, Noboru T, Margaret BE, Ernst SJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177(2), 219–234 (2004).
  MedlineGoogle Scholar
• 47. Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr. Med. Res. Opin. 23(12), 3055–3068 (2007).
  Medline CASGoogle Scholar
• 48. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS trial). Am. J. Cardiol. 99(11), 1538–1543 (2007).
  Medline CASGoogle Scholar
• 49. Ferdinand KC, Clark LT, Watson KE et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am. J. Cardiol. 97(2), 229–235 (2006).
  Medline CASGoogle Scholar
• 50. Ramon L, Yčas J, Michael S, Haffner S. STARSHIP Study Group Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am. J. Cardiol. 98(6), 768–773 (2006).
  MedlineGoogle Scholar
• 51. Chapman N, Chang CL, Caulfield M et al. Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn. Dis. 21(2), 150–157 (2011).
  MedlineGoogle Scholar
• 52. Gandelman K, Fung GL, Messig M, Laskey R. Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am. J. Ther. 19(3), 164–173 (2012).
  MedlineGoogle Scholar
• 53. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J. Atheroscler. Thromb. 24(1), 19–25 (2017).
  MedlineGoogle Scholar
• 54. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368(9542), 1155–1163 (2006).
  Medline CASGoogle Scholar
• 55. Li YF, Feng QZ, Gao WQ, Zhang XJ, Huang Y, Chen YD. The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report. BMC Cardiovasc. Disord. 15, 6 (2015).
  MedlineGoogle Scholar
• 56. Lee E, Ryan S, Birmingham B et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78(4), 330–341 (2005).
  Medline CASGoogle Scholar
• 57. Tomita Y, Maeda K, Sugiyama Y. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin. Pharmacol. Ther. 94(1), 37–51 (2013).
  Medline CASGoogle Scholar
• 58. Warrington S, Nagakawa S, Hounslow N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an openlabel, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. Clin. Drug Investig. 31, 735–743 (2011).
  Medline CASGoogle Scholar
• 59. Ho RH, Choi L, Lee W et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics 17(8), 647–56 (2007).
  Medline CASGoogle Scholar
• 60. Birmingham BK, Bujac SR, Elsby R et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur. J. Clin. Pharmacol. 71(3), 329–340 (2015).
  Medline CASGoogle Scholar
• 61. Bahadir MA, Oguz A, Uzunlulu M, Bahadir O. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J. Atheroscler. Thromb. 16(5), 684–690 (2009).
  Medline CASGoogle Scholar
• 62. Nishikido T, Oyama J-I, Keida T, Ohira H, Node K. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: the Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. J. Cardiol. 67(4), 340–346 (2016).
  MedlineGoogle Scholar
• 63. Clementia A, Kim JC, Florisa M et al. Statin therapy is associated with decreased small, dense low-density lipoprotein levels in patients undergoing peritoneal dialysis. Contrib. Nephrol. 178, 111–115 (2012).
  MedlineGoogle Scholar
• 64. Choi CU, Seo HS, Lee EM et al. Statins do not decrease small, dense low-density lipoprotein. Tex. Heart Inst. J. 37(4), 421–428 (2010).
  MedlineGoogle Scholar
• 65. O'Neal DN, Piers LS, Iser DM et al. Australian Aboriginal people and Torres Strait Islanders have an atherogenic lipid profile that is characterised by low HDL-cholesterol level and small LDL particles. Atherosclerosis 201(2), 368–377 (2008).
  MedlineGoogle Scholar
• 66. Crestor^®, package insert. AstraZeneca Pharmaceuticals, DE, USA.
  Google Scholar
• 67. Hua WJ, Hua WX, Fang HJ. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc. Ther. 30(5), e234–e241 (2012).
  Medline CASGoogle Scholar
• 68. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47(5), 566–578 (2007).
  Medline CASGoogle Scholar
• 69. Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme A reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12), 1537–1544 (2008).
  Medline CASGoogle Scholar
• 70. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118(4), 355–362 (2008).
  Medline CASGoogle Scholar
• 71. Chung JY, Cho SK, Oh ES et al. Effect of HMGCR variant alleles on low-density lipoprotein cholesterol: lowering response to atorvastatin in healthy Korean subjects. J. Clin. Pharmacol. 52(3), 339–346 (2012).
  Medline CASGoogle Scholar
• 72. Hiura Y, Tabara Y, Kokubo Y et al. Association of the functional variant in the 3-hydroxy-3-methylglutaryl-coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese. Circ. J. 74(3), 518–522 (2010).
  Medline CASGoogle Scholar
• 73. Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12), 1537–1544 (2008).
  Medline CASGoogle Scholar
• 74. Williams JA, Ring BJ, Cantrell VE et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30(8), 883–891 (2002).
  Medline CASGoogle Scholar
• 75. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 38(9), 1240–1251 (2008).
  Medline CASGoogle Scholar
• 76. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin. Pharmacol. Ther. 102(4), 688–700 (2017).
  Medline CASGoogle Scholar
• 77. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274–286 (2011).
  MedlineGoogle Scholar
• 78. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. The CYP3A4 intron 6 C >T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J. Toxicol. Sci. 38(3), 349–354 (2013).
  Medline CASGoogle Scholar
• 79. Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12), 861–866 (2011).
  Medline CASGoogle Scholar
• 80. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 47(1), 87–93 (2007).
  Medline CASGoogle Scholar
• 81. Kivisto KT, Niemi M, Schaeffeler E et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14(8), 523–525 (2004).
  MedlineGoogle Scholar
• 82. Rosdi RA, Mohd Yusoff N, Ismail R et al. High allele frequency of CYP2C9*3 (rs1057910) in a Negrito’s subtribe population in Malaysia; Aboriginal people of Jahai. Ann. Hum. Biol. 43(5), 445–450 (2016).
  MedlineGoogle Scholar
• 83. Li Z-q, Li C-y, Wan X, Wang F. Effect of CYP2C9*3 gene polymorphism on lipid-lowering efficacy of fluvastatin in a Chinese hyperlipidemic population. Trop. J. Pharm. Res. 16(9), 2261–2265 (2017).
  CASGoogle Scholar
• 84. Skvrce NM, Bozina N, Zibar L, Barisic I, Pejnovic L, Sarinic VM. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case–control study. Pharmacogenomics 14(12), 1419–1431 (2013).
  Google Scholar
• 85. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276(38), 35669–35675 (2001).
  Medline CASGoogle Scholar
• 86. Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmacogenomics Pers. Med. 9, 97–106 (2016).
  Medline CASGoogle Scholar
• 87. Tachibana-Iimori R, Tabara Y, Kusuhara H et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19(5), 375–380 (2004).
  Medline CASGoogle Scholar
• 88. Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet. Genomics. 20(3), 211–216 (2010).
  Medline CASGoogle Scholar
• 89. Kim SR, Saito Y, Sai K et al. Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Drug Metab. Pharmacokinet. 22(6), 456–461 (2007).
  MedlineGoogle Scholar
• 90. Mwinyi J, Köpke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur. J. Clin. Pharmacol. 64(3), 257–266 (2008).
  Medline CASGoogle Scholar
• 91. Marja Pasanen. Pharmacogenetics of SLCO1B1: population genetics and effect on statins [PhD thesis]. University of Helsinki, Finland (2008).
  Google Scholar
• 92. Jada SR, Xiaochen S, Yan LY et al. Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur. J. Clin. Pharmacol. 63(6), 555–563 (2007).
  Medline CASGoogle Scholar
• 93. Chang C, Pang KS, Swaan PW, Ekins S. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J. Pharmacol. Exp. Ther. 314(2), 533–541 (2005).
  Medline CASGoogle Scholar
• 94. Nozawa T, Nakajima M, Tamai I et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302(2), 804–813 (2002).
  Medline CASGoogle Scholar
• 95. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87(1), 130–133 (2010).
  Medline CASGoogle Scholar
• 96. Deng JW, Song IS, Shin HJ et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet. Genomics 18(5), 424–433 (2008).
  Medline CASGoogle Scholar
• 97. Chung JY, Cho JY, Yu KS et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78(4), 342–350 (2005).
  Medline CASGoogle Scholar
• 98. Ieiri I, Suwannakul S, Maeda K et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 82(5), 541–547 (2007).
  Medline CASGoogle Scholar
• 99. Nishizato Y, Ieiri I, Suzuki H et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73(6), 554–565 (2003).
  Medline CASGoogle Scholar
• 100. Niemi M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14(7), 429–440 (2004).
  Medline CASGoogle Scholar
• 101. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83(2), 251–257 (2008).
  Medline CASGoogle Scholar
• 102. Group TSC. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N. Engl. J. Med. 359(8), 789–799 (2008).
  MedlineGoogle Scholar
• 103. Brunham LR, Lansberg PJ, Zhang L et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3), 233–237 (2012).
  Medline CASGoogle Scholar
• 104. Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case–control studies. Medicine (Baltimore) 94(37), e1268 (2015).
  Medline CASGoogle Scholar
• 105. US FDA. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. (2011). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor#Simvastatin_Dose_Limitations
  Google Scholar
• 106. Wilke RA, Ramsey LB, Johnson SG et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112–7 (2012).
  Medline CASGoogle Scholar
• 107. Bank PCD, Caudle KE, Swen JJ et al. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin. Pharmacol. Ther. 103(4), 599–618 (2018).
  Medline CASGoogle Scholar
• 108. Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet. Med. 16(11), 810–819 (2014).
  Medline CASGoogle Scholar
• 109. Soko ND, Masimirembwa C, Dandara C. Pharmacogenomics of rosuvastatin: a glocal (global + local) African perspective and expert review on a statin drug. OMICS 20(9), 498–509 (2016).
  Medline CASGoogle Scholar
• 110. Umamaheswaran G, Kumar DK, Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters: a review with Indian perspective. Indian J. Med. Res. 139(1), 27–65 (2014).
  Medline CASGoogle Scholar
• 111. Griese EU, Ilett KF, Kitteringham NR et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics 11(1), 69–76 (2001).
  Medline CASGoogle Scholar
• 112. Wiggins BS, Saseen JJ, Page RL II et al. Recommendations for management of clinically significant drug–drug interactions with statins and select agents used in patients with cardiovascular disease. Circulation 134, e1–e28 (2016).
  MedlineGoogle Scholar
• 113. Tulner LR, Frankfort SV, Gijsen GJPT, van Campen JPCM, Koks CHW, Beijnen JH. Drug–drug interactions in a geriatric outpatient cohort. Drugs Aging 25(4), 343–355 (2008).
  MedlineGoogle Scholar
• 114. Yoon D, Sheen SS, Lee S, Choi YJ, Park RW, Lim H-S. Statins and risk for new-onset diabetes mellitus: a real-world cohort study using a clinical research database. Medicine 95(46), e5429 (2016).
  Medline CASGoogle Scholar
• 115. Ian Hamilton-Craig. Something you should know about statins and heart disease. (2013). https://theconversation.com/some-things-you-should-know-about-statins-and-heart-disease-19655
  Google Scholar
• 116. Zaveri HG, Mansuri SM, Patel VJ. Use of potentially inappropriate medicines in elderly: a prospective study in medicine out-patient department of a tertiary care teaching hospital. Indian J. Pharmacol. 42(2), 95–98 (2010).
  Medline CASGoogle Scholar
• 117. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41(5), 343–370 (2002).
  Medline CASGoogle Scholar
• 118. Gabb GM, Vitry A, Condon A, Limaye V, Alhami G. Serious statin associated myotoxicity and rhabdomyolysis in Aboriginal and Toress Strait Islanders: a case series. Intern. Med. J. 43(9), 987–992 (2013).
  Medline CASGoogle Scholar
• 119. FDA PI. Statins 2016. http://www.accessdata.fda.gov
  Google Scholar
• 120. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585–2590 (2004).
  Medline CASGoogle Scholar
• 121. Wiggins BS, Saseen JJ, Page RL et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 134, e468–e495 (2016).
  MedlineGoogle Scholar
• 122. Michael BB. Statin safety and drug interactions: clinical implications. Am. J. Cardiol. 97(8), S27–S31 (2006).
  Google Scholar
• 123. Stroes ES, Thompson PD, Corsini A et al. Statin-associated muscle symptoms: impact on statin therapy: European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur. Heart J. 36(17), 1012–1022 (2015).
  Medline CASGoogle Scholar
• 124. Day J, Limaye V. Over-representation of statin-associated necrotising myopathy in patients of Aboriginal and Torres Strait Islander heritage. Intern. Med. J. 48(6), 749–751 (2018).
  MedlineGoogle Scholar
• 125. Caughey GE, Gabb GM, Ronson S et al. Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population. JAMA Intern. Med. 178(9), 1224–1229 (2018).
  MedlineGoogle Scholar
• 126. Clark KEN, Isenberg DA. A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur. J. Neurol. 25, 13–23 (2018).
  Medline CASGoogle Scholar
• 127. Khan NAJ, Khalid S, Ullah S, Malik MU, Makhoul S. Necrotizing autoimmune myopathy: a rare variant of idiopathic inflammatory myopathies. J.Investig. Med. High Impact Case Rep. 5(2), 2324709617709031 (2017).
  Google Scholar
• 128. Woolley M, Stebbings S, Highton J. Statin-associated immune-mediated necrotizing myopathy: a New Zealand case series showing possible overrepresentation in Pacific Islanders. Intern. Med. J. 48(1), 32–36 (2018).
  Medline CASGoogle Scholar
• 129. Nichols L, Pfeifer K, Mammen AL, Shahnoor N, Konersman CG. An unusual case of statin-induced myopathy: anti-HMGCoA necrotizing autoimmune myopathy. J. Gen. Intern. Med. 30(12), 1879–1883 (2015).
  MedlineGoogle Scholar
• 130. Dixit A, Abrudescu A. A case of atorvastatin-associated necrotizing autoimmune myopathy, mimicking idiopathic polymyositis. Case Rep.Rheumatol. 2018, 5931046 (2018).
  MedlineGoogle Scholar
• 131. Troyanov Y, Landon-Cardinal O, Fritzler MJ et al. Atorvastatin-induced necrotizing autoimmune myositis: an emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype. Medicine 96(3), e5694 (2017).
  Medline CASGoogle Scholar
• 132. Limaye V, Bundell C, Hollingsworth P et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52(2), 196–203 (2015).
  Medline CASGoogle Scholar
• 133. Mammen AL, Gaudet D, Brisson D et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. (Hoboken) 64(8), 1233–1237 (2012).
  Medline CASGoogle Scholar
• 134. Lester S, Cassidy S, Humphreys l et al. Evolution in HLA-DRB1 and major histocompatibility complex class II haplotypes of Australian aborigines definition of a new DRB1 allele and distribution of DRB 1 gene frequencies. Hum. Immunol. 42(2), 154–160 (1995).
  Medline CASGoogle Scholar
• 135. Gao X, Veale A, Serjeantson SW. HLA class II diversity in Australian aborigines: unusual HLA-DRB 1 alleles. Immunogenetics 36, 333 (1992).
  Medline CASGoogle Scholar
• 136. Ayo CM, da Silveira Camargo AV, Xavier DH et al. Frequencies of allele groups HLA-A, HLA-B and HLA-DRB1 in a population from the northwestern region of São Paulo State, Brazil. Int. J. Immunogenet. 42(1), 19–25 (2015).
  Medline CASGoogle Scholar
• 137. Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J. Clin. Med. 9, 22 (2020).
  CASGoogle Scholar
• 138. Rider LG, Shamim E, Okada S et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites. Arthritis & Rheumatism 42(6), 1285–1290 (1999).
  Medline CASGoogle Scholar
• 139. O'Hanlon TP, Rider LG, Mamyrova G et al. HLA polymorphisms in African–Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis & Rheumatism 54(11), 3670–3681 (2006).
  MedlineGoogle Scholar
• 140. Wood D, DeBacker G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140, 199–270 (1998).
  Medline CASGoogle Scholar
• 141. Thynne T, Gabb GM. Therapeutic drug safety for Indigenous Australians: how do we close the gap? Med. J. Aust. 204(1), 16–17 (2016).
  MedlineGoogle Scholar
• 142. Hayman N. Improving Aboriginal and Torres Strait Islander people’s access to the Pharmaceutical Benefits Scheme. Aust. Prescr. 34, 38–40 (2011).
  Google Scholar
• 143. Australian Indigenous Health Info Net. Overview of Australian Aboriginal and Torres Strait Islander health status, 2017 (2018). Available from: https://healthinfonet.ecu.edu.au/learn/health-facts/overview-aboriginal-torres-strait-islander-health-status/
  Google Scholar